How to Buy Nektar Therapeutics Stock
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.
Nektar Therapeutics stock last closed at $0.66, up 6.07% from the previous day, and has decreased 51.18% in one year. It has overperformed other stocks in the Biotechnology industry by 0.26 percentage points. Nektar Therapeutics stock is currently +53.7% from its 52-week low of $0.43, and -65.56% from its 52-week high of $1.93.
There are currently 186.1M NKTR shares outstanding. The market capitalization of NKTR is $123.57M. In the past 24 hours, 1.07M NKTR shares were traded.
How to Buy Nektar Therapeutics Stock
Not sure how to invest in Nektar Therapeutics stock? Here's how.
- Decide where to buy Nektar Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Nektar Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Pick your method of payment and add your info.
- Evaluate Nektar Therapeutics stock: The Nektar Therapeutics ticker symbol is NKTR. Is Nektar Therapeutics stock a good investment? Should you buy shares of NKTR? How do NKTR's underlying business fundamentals look? Do top analysts think Nektar Therapeutics is a good buy? Why has NKTR's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if NKTR is a good stock to buy).
- Execute your NKTR buy order: Decide if you will purchase NKTR shares at the current market price or use a limit order to buy NKTR shares at a specific price.
- Get notifications regarding your NKTR investment: Create a watchlist to track your new investment in Nektar Therapeutics shares.
Step 1: Decide where to buy Nektar Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy NKTR stock.
Our preferred brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Utilities, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the right brokerage, you need to fill out some personal info so you can buy NKTR today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new trading account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have opened your account on the best beginner stock app, you need to deposit funds:
Watch the video below for more details depositing money into your new brokerage account.
Step 4: Evaluate Nektar Therapeutics stock
Once you have decided on the best place to buy Nektar Therapeutics stock, it's important to evaluate their stock before you invest, so you can wrap your head around the risk as well as the upside.
Nektar Therapeutics quick stats
Nektar Therapeutics Due Diligence Checks
WallStreetZen was built to help average investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on NKTR's stock page.
Is NKTR stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge NKTR's true value.
Using relative valuations measures:
- NKTR may be undervalued based on its P/B ratio of 2.03x, relative to Biotechnology industry P/B ratio of 4.16x
You can do additional valuation analysis on NKTR's stock here.
NKTR Financial Summary
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the NKTR balance sheet.
- There are more short-term assets than short-term liabilities on the NKTR balance sheet.
- NKTR has $255.23M in cash and short term investments. This is enough to cover its annual cash burn of $111.79M.
- NKTR has cash burn of 111791000. It has sufficient cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- Total NKTR debt is higher than 5 years ago, relative to shareholder equity.
- NKTR has a relatively high debt to equity ratio of 4.
- NKTR profit margin has gone up by 1.85 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy NKTR stock
Out of 5 Equities analysts who monitor NKTR, the consensus analyst rating on Nektar Therapeutics is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Nektar Therapeutics stock forecast page.
NKTR Momentum
How is NKTR performing as a company?
Last year, NKTR revenue was $98.43M. Over the last five year, NKTR's revenue has gone up by -3% per year. This was slower than the Biotechnology industry average of 44.4%.
Find out more about NKTR's earnings and revenue performance here.
Who is buying/selling NKTR?
In the past 12 months, executives and large shareholders at NKTR have sold more shares than they have bought.
Howard W. Robin, President CEO of NKTR, was the latest NKTR insider to sell. They sold $24,011.74 worth of NKTR shares on Feb 19, 2025.
Get more info about who owns NKTR shares here.
Does NKTR stock generate passive income?
No, Nektar Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your NKTR buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price, use a limit order.
Press the Open button and your broker will execute your order.
If you require additional help with buying stocks on eToro, watch the helpful video below:
Step 6: Get notifications regarding your NKTR investment
Now that you own some NKTR shares, you'll want to keep up with your new shares.
Start a watchlist to keep track of your NKTR stock.
NKTR Feed
How to Buy Stock in Nektar Therapeutics
To summarize, here are the 6 steps to buy stock in Nektar Therapeutics:
- Decide where to buy Nektar Therapeutics stock
- Open your brokerage account
- Deposit money your investment account
- Evaluate Nektar Therapeutics stock
- Execute your NKTR buy order
- Get notifications regarding your NKTR investment
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your new investment in Nektar Therapeutics, click below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.